SCHEMBL16618142

SCHEMBL16618142

COC(=O)[C@@H]1CC2CC2C[C@H]1C(=O)Cc1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
HTT P42858 2/20 0.50
L3MBTL1 Q9Y468 3/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 1/20 0.38
CASP3 P42574 1/20 0.38
ATM Q13315 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16618143 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HTTL3MBTL1KDM4E
SCHEMBL16617648 0.84 HPGD (0.40) ALDH1A1SMN1; SMN2HTTL3MBTL1HPGD
SCHEMBL16618196 0.83 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2HTTL3MBTL1KDM4E
SCHEMBL16618194 0.83 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2HTTL3MBTL1KDM4E
SCHEMBL17592783 0.75 CA1 (0.49) ALDH1A1SMN1; SMN2HTTL3MBTL1KDM4E
SCHEMBL17592530 0.75 CA1 (0.49) ALDH1A1SMN1; SMN2HTTL3MBTL1KDM4E
SCHEMBL17592531 0.75 CA1 (0.49) ALDH1A1SMN1; SMN2HTTL3MBTL1KDM4E
SCHEMBL17593107 0.72 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2HTTCYP3A4TSHR
SCHEMBL17593108 0.72 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2HTTCYP3A4TSHR
SCHEMBL16617292 0.72 CYP3A4 (0.44) SMN1; SMN2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
EP-3055314-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ ALDH1A1 4582/4885SMN1; SMN2 4512/4885HTT 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.